Navigation Links
Ondine to Present at Canaccord Adams 28th Annual Global Growth Conference
Date:8/6/2008

VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that its Chief Technology Officer, Dr. Nicolas Loebel, is scheduled to present at the 28th Annual Canaccord Adams Global Growth Conference at the Intercontinental Hotel in Boston, on Tuesday August 12th, 2008 at 1:00 p.m. Eastern Time.

Interested parties may access the live webcast by visiting the Company's website at http://www.ondinebiopharma.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software downloads that may be required to join the webcast. An audio archive of the presentation will be available for approximately 60 days.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development facility in Bothell, Washington, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: http://www.ondinebiopharma.com

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.


'/>"/>
SOURCE Ondine Biopharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
2. Atrium Innovations to Present at Upcoming 28th Annual Canaccord Adams Global Growth Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
4. Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
8. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
9. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/10/2016)... - BioAmber Inc. (NYSE: BIOA ), a leader ... & Co. Ltd., its partner in the ... an additional CDN$25 million in the joint venture for ... to 40%.  Mitsui will also play a stronger role ... Sarnia , providing dedicated resources alongside BioAmber,s ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model which will ... of joining or renewing through an organizational purchasing model. ... every employee in any size association or AMC office ... member benefits.   John H. Graham, IV ... allow organizations of any size and their employees to ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
Breaking Biology Technology:
(Date:2/9/2016)... -- Vigilant Solutions announces today that an agency used its ... lead in a difficult homicide case. The agency then used ... suspect vehicle. Due to the ongoing investigation, the agency name ... the agency,s request. --> --> ... found deceased at an intersection here in the City. He ...
(Date:2/5/2016)... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... has announced the addition of the ... to their offering. --> Research ... the addition of the "Global Facial ...
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
Breaking Biology News(10 mins):